Crohn's Disease, IBD
Conditions
Brief summary
Crohn's disease and ulcerative colitis affect about 1.6 to 3 million people in the United States with many of those being young children and adolescents. Physicians need better ways to inform decisions on therapy selection and recognize ongoing intestinal injury while on treatment. The main reason for this research study is to see if a blood test or stool test, which measures specific proteins, taken just before starting a new treatment for Crohn's disease can predict a patient's ability to achieve complete intestinal healing. The investigators also want to see if the intensity of gut inflammation can be detected by measuring a separate set of proteins in the blood.
Detailed description
Despite the heterogeneity of CD phenotypes and a potentially aggressive course of inadequately treated CD, treatment selection for newly diagnosed patients is currently based on clinical factors which do not define CD sub-types. Now, with additional biologic therapies for CD, there is a critical need for individual biochemical analysis both pre-treatment, and following induction to assess the probability of durable remission. These data will inform decisions on continued dosing of the current biologic, or whether addition of combination therapy or switching to a therapy with an alternative mechanism of action will be more beneficial. The Food & Drug Administration (FDA) defines a companion diagnostic as a device that can identify patients most likely to benefit from a therapy or a device to monitor response with the purpose to adjust the treatment to achieve improved effectiveness.Our global aim is to develop a companion diagnostic (peripheral blood panel) that accurately predicts the probability of deep remission (clinical remission with MH) to anti-TNF and a protein (blood) biomarker panel that reproducibly distinguishes endoscopic MH from active (ulcerated) intestinal inflammation in patients with CD. The long-term strategy is to utilize the low-risk anti-TNF specific module (protein panel) to personalize CD therapy. With the addition of new biologics for CD, patients with a low-risk inflammatory profile would not only be expected to achieve MH but also predicted to respond to treatment escalation strategies while avoiding or stopping the drug (if drug exposure is optimized) sooner in patients in which the protein profile predicts a low probability of deep remission with anti-TNF. As additional therapies are approved for pediatric CD, the priority would be to avoid anti-TNF in patients with a high-risk protein profile and specifically select therapies that target the patient's individual inflammatory signature. Additionally, the investigators expect the protein profile of patients failing to achieve deep remission to provide further insight into molecular mechanisms contributing to the continued inflammation and thereby directing the next therapeutic option.
Interventions
DRUGInfliximab
No standard dosing regimen will be used and the dose will be determined by the treating physician
DRUGAdalimumab
No standard dosing regimen will be used and the dose will be determined by the treating physician
Sponsors
The Leona M. and Harry B. Helmsley Charitable Trust
Children's Hospital Medical Center, Cincinnati
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Years to 22 Years
Healthy volunteers
Yes
Inclusion criteria
Phase I - Cross-sectional Study (CD and Suspected IBD) Inclusion Criteria: 1. Age criteria: \> 1 year to \< 22 years of age 2. Diagnosis of Crohn's disease, anti-TNF naïve, and colonoscopy scheduled OR 3. Clinical suspicion for IBD (treatment naïve) and colonoscopy scheduled 4. Permission of parent/guardian and assent or consent of research participant
Exclusion criteria
1. Any prior treatment with an anti-TNF, such as infliximab, adalimumab, certolizumab or golimumab 2. Known diagnosis of ulcerative colitis (UC) or inflammatory bowel disease-unspecified (IBD-U) 3. Active or prior evidence of internal (abdominal/pelvic) penetrating fistula(e) 4. Active intra-abdominal abscess or perianal abscess 5. Active Clostridium difficile infection or other known enteric infection in last 2 weeks 6. Current ileostomy or colostomy, extensive small bowel resection, ileoanal pouch or short bowel syndrome 7. History of autoimmune disease (including autoimmune hepatitis, primary sclerosing cholangitis, thyroiditis, psoriasis or juvenile idiopathic arthritis) 8. Any condition that in the opinion of the PI will prevent the research participant from taking part in this study Phase I - Cross-sectional Study (healthy volunteers) Inclusion Criteria: 1. Age criteria: \> 1 year to \< 22 years of age 2. Any CCHMC patient 3. Permission of parent/guardian and assent or consent of research participant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sustained Deep Remission | 1 year | Sustained Deep Remission, defined as meeting all of the following at 1 year (check all that apply): * no wPCDAI score of ≥12.5 on two consecutive visits between week 30-52 * wPCDAI at week 52 is \<12.5 * off prednisone between weeks 30-52 * endoscopic remission (SES-CD\<3) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| End of Induction Outcomes: Clinical Remission | Week 16 | wPCDAI \<12.5 at Week 16 |
| End of Induction Outcomes: Steroid Free Clinical Remission | Week 16 | wPCDAI \<12.5 and off prednisone by Week 16 |
| End of Induction Outcomes: Fecal Biochemical Response | Week 16 | Fecal calprotectin improved \>50% from baseline stool (+/- 30 days from Week 16) |
| End of Induction Outcomes: Fecal Biochemical Remission | Week 16 | Fecal calprotectin \<250µg/g at Week 16 (+/- 30 days) |
| End of Induction Outcomes: Blood CRP Biochemical Remission | Week 16 | CRP \<0.5 mg/dL at Week 16 |
| End of Induction Outcomes: Blood CD64 Biochemical Remission | Week 16 | nCD64 \<4.5 at Week 16 |
| Week 52 Outcomes: Endoscopic Response | 1 year | 50% reduction in SES-CD score from baseline SES-CD (if performed) |
| Week 52 Outcomes: Endoscopic Remission | 1 year | SES-CD \<3 |
| Week 52 Outcomes: Minimal Endoscopic Activity | 1 year | SES-CD \<6 with no individual SES-CD subscore \>1 |
| Week 52 Outcomes: Complete Intestinal Healing | 1 year | SES-CD = 0 |
| Week 52 Outcomes: Sustained, Steroid-free Clinical Remission | 1 year | wPCDAI \<12.5 for all visits from weeks 30-52, off prednisone |
| End of Induction Outcomes: Clinical Response | Week 16 | Improvement of \>17.5 points from baseline wPCDAI and/or Week 16 wPCDAI= \<12.5 points |
| Week 52 Outcomes: Clinical Remission and Endoscopic Response | 1 year | wPCDAI \<12.5 at week 52 and SES-CD\>50% reduction from baseline |
| Week 52 Outcomes: Clinical Remission and Minimal Endoscopic Activity | 1 year | wPCDAI \<12.5 at week 52 and SES-CD\<6 with no individual SES-CD subscore \>1 |
| Week 52 Outcomes: Treatment Response | 1 year | continues on anti-TNF without surgery, hospitalization and off prednisone by week 16 |
| Week 52 Outcomes: Transmural ileal healing | 1 year | ileum subscore stage 0 (score = 0) or stage 1 (score 1-3) |
| Week 52 Outcomes: Transmural colonic healing | 1 year | all segments of colon subscore stage 0 (score=0) or stage 1 (score 1-3) |
| Week 52 Outcomes: Total Bowel Transmural healing | 1 year | total ileum and colonic subscore is not greater than stage 1 on either individual score |
| Week 52 Outcomes: Fecal Biochemical Remission | 1 year | fecal calprotectin \<250 µg/g at week 52 |
| Week 52 Outcomes: Deep Fecal Biochemical Remission | 1 year | fecal calprotectin \<150 µg/g at week 52 |
| Week 52 Outcomes: CRP Biochemical Remission | 1 year | CRP \<0.5 mg/dL at week 52 |
| Week 52 Outcomes: CD64 Biochemical Remission | 1 year | nCD64 \<4.5 at week 52 |
| Week 52 Outcomes: PGA Remission | 1 year | physician-rated PGA is quiescent and subject is off prednisone |
| Week 52 Outcomes: Clinical Remission | 1 year | wPCDAI \<12.5 and off prednisone at last study visit |
Countries
United States
Outcome results
None listed